A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
BackgroundIn newly diagnosed glioblastoma, radiation with concurrent and adjuvant (six cycles) temozolomide (TMZ) is the established standard of postsurgical care. However, the benefit of extending adjuvant TMZ therapy beyond six cycles has remained unknown.MethodsWe searched PubMed, Web of Science,...
Guardado en:
Autores principales: | Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f17fce4fc254ad2adfc4a8556712e0d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>
por: María del Mar Álvarez-Torres, et al.
Publicado: (2021) -
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide
por: Yiming Ding, et al.
Publicado: (2021) -
Novel cancer stem cell marker MVP enhances temozolomide-resistance in glioblastoma
por: Kum Hee Noh, et al.
Publicado: (2022) -
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Luca X. Zampieri, et al.
Publicado: (2021) -
Treatment options and outcomes for glioblastoma in the elderly patient
por: Arvold ND, et al.
Publicado: (2014)